Ubie, a Tokyo, Japan-based healthcare AI startup, announced that it raised $19 million in Series C extension, and closed its Series C at $45 million.
The extension round money was raised from SOGO MEDICAL CO., LTD., AAIC Investment Pte. Ltd., Japan Impact Investment II Limited Partnership, and Rakuten Capital, while loans extended from the Shoko Chukin Bank, Ltd., Japan Finance Corporation, and Mizuho Bank, Ltd.
The new funding will enable Ubie to accelerate its growth and strengthen its presence in the U.S., following strong interest and traction in that market. To date, Ubie has raised $76 million in total.
Ubie, with the mission of "guiding people to appropriate medical care with technology," is one of the few companies in the world having direct contact with both patients and medical institutions. It will also focus on expanding its business to the U.S. in order to apply the technology it has developed in Japan, one of the leading countries in the medical field.
It established a local subsidiary in New York on October 4, 2022, using Series C funding. This is the second overseas corporation following Singapore. The decision is based on the fact that the number of users has steadily increased since the release of the AI symptom checker in the United States in April 2022.
The establishment of the local subsidiary will further strengthen the partnership with U.S. pharmaceutical companies, and the products, including hiring local people in the U.S.
Company: Ubie, Inc.
Raised: $19.0M
Round: Series C Extension
Funding Month: December 2022
Lead Investors: SOGO MEDICAL CO., LTD., AAIC Investment Pte. Ltd., Japan Impact Investment II Limited Partnership, and Rakuten Capital
Additional Investors: Shoko Chukin Bank, Ltd., Japan Finance Corporation, and Mizuho Bank, Ltd
Company Website: https://company.ubiehealth.com/
Software Category: Healthcare AI
About the Company: Ubie is a Japanese health-tech startup founded by Abe Yoshinori and Kubo Kota in 2017. It provides AI-based healthcare products, hospital SaaS products, and AI symptom checkers. Using AI as its core technology, the company develops and provides an AI-powered patient questionnaire that guides patients from symptoms to appropriate medical care and improves operational efficiency in the medical field. Ubie is promoting the creation of a society in which anyone can access medical care that suits them best. Ubie already has business with more than 20 major pharmaceutical companies in Japan and other countries. The company’s vision is to create a world where good health is easily accessible to everyone as air.
Source: https://company.ubiehealth.com/press-release/press-12082022